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Abstract 
Objectives: The relationship between the timing of antibiotics and mortality among sepsis shock patients 
has not been examined among patients specifically with Staphylococcus aureus (S. aureus) bacteremia.  
Design: Retrospective analysis of a Veterans Affairs S. aureus bacteremia database.  
Setting: One hundred twenty-two hospitals in the VA Health System.  
Patients: Patients with septic shock and S. aureus bacteremia admitted directly from the emergency 
department to the intensive care unit from January 1, 2003 to October 1, 2015 were evaluated.  
Intervention: Time to appropriate antibiotic administration and 30-day mortality.  
Measurements and Main Results: A total of 506 patients with S. aureus bacteremia and septic shock were 
included in the analysis.  Thirty-day mortality was 78.1% for the entire cohort and was similar for those 
participants with methicillin resistant (MRSA) and methicillin sensitive S. aureus (MSSA) bacteremia.  Our 
multivariate analysis revealed that as compared to those who received appropriate antibiotics within one 
hour after ED presentation, each additional hour that passed before appropriate antibiotics were 
administered produced an odds ratio of 1.11 [95% CI: 1.02-1.21] of mortality within 30 days. This odds 
increase equates to an average adjusted mortality increase of 1.3% [95% CI: 0.4% - 2.2%] for every hour 
that passes before antibiotics are administered. 
Conclusions: The results of this study further support the importance of prompt appropriate antibiotic 
administration for patients with septic shock.  Physicians should consider acting quickly to administer 
antibiotics with S. aureus coverage to any patient suspected of having septic shock.  
Key Words: Staphylococcus aureus; antibiotics; septic shock  
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Manuscript 
Introduction 
Sepsis is a significant global public health burden that afflicts over 31 million people and causes an 
estimated 5.3 million deaths annually [1].  International guidelines and federal quality measures call for 
timely administration of antibiotics to septic patients [2,3], and in the case of septic shock, now advise that 
they be given within the first hour [4].   
Initial studies examining the relationship between time to antibiotics and sepsis mortality produced 
mixed results, but suggest a benefit from early antibiotic administration [5-19]. Two subsequent studies that 
examined large state-wide databases provide the most compelling evidence that early administration of 
antibiotics saves lives.  A 2017 study of 35,000 septic patients in a California healthcare system showed that 
delays in antibiotic administration were associated with increased mortality [20]. The association was most 
pronounced among septic shock patients who suffered a 1.8% increase in the probability of mortality for 
each hour antibiotics were not provided.  Additionally, an analysis of the New York State Sepsis Initiative 
revealed that timely completion of a sepsis bundle was associated with reduced mortality among septic 
patients [21]. Of the sepsis bundle components, early antibiotic administration was the component most 
strongly associated with the observed decrease in mortality.  
Previous studies that evaluated the relationship between the timing of antibiotics and mortality 
among sepsis patients have, with one exception [19], studied a cohort of patients with sepsis from a variety 
of bacterial species.  To date, the relationship between the timing of antibiotic administration and sepsis 
morality has not been examined among septic shock patients with Staphylococcus aureus (S. aureus) 
bacteremia.  Both methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA), are a 
leading cause of sepsis due to skin and soft tissue infections, endocarditis, osteoarticular infections, 
pneumonia, toxic shock syndrome, and line or medical device infections [22].  MRSA bacteremia is 
independently associated with sepsis mortality [23, 24]. Among critically-ill patients with MRSA 
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bacteremia mortality rates can exceed 60% [25].  Given the high rate of mortality among septic patients 
infected with S. aureus, it is important to determine if the relationships observed previously among patients 
with a heterogenous bacterial sepsis source also hold for those with S. aureus bacteremia. 
We studied the relationship between the time of appropriate antibiotic administration following 
emergency department triage and mortality among patients with septic shock admitted to the intensive care 
unit (ICU) whose blood cultures revealed a S. aureus infection.  We then examined the effects that MRSA 
and MSSA had on our findings.  
 
Methods 
 
Participants, data source, and data elements  
We conducted a retrospective study of adult patients (age > 18 years) with S. aureus (MRSA or 
MSSA) bacteremia admitted to 122 hospitals in the Veterans Affairs (VA) Health System from January 1, 
2003 to October 1, 2015. We included patients who fulfilled the 2001 International Sepsis Definitions 
(Sepsis-2) for septic shock [26] using the International Classification of Disease Clinical Modification 9th 
edition diagnosis codes: 785.52 [27]. We included only those patients who presented to the emergency 
department (ED) with sepsis, were admitted directly to the intensive care unit (ICU), and received 
appropriate antibiotics.  We excluded patients in whom establishing a “time zero” for antibiotic 
administration is difficult. This included patients who developed septic shock on a medical or surgical ward, 
were transferred from an outside hospital, or were directly admitted from an outpatient setting to the 
hospital.  Patients who first received antibiotics more than 12 hours after ED triage were excluded since it is 
possible that these patients developed sepsis following admission to the ICU (Figure #1).  Limiting the 
sample to ED patients admitted to the ICU enabled us to focus on those patients for whom a clear and 
reproducible “time zero” could be identified for tracking the time elapsed prior to antibiotic administration.   
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Clinical data for study participants were obtained from the national VA databases through a review 
of the electronic medical record (EMR) using automated electronic data extraction.  Medical history and 
clinical characteristics extracted from each participant’s EMR included: microbiologic and chemistry 
laboratory data, vital signs, the Acute Physiology and Chronic Health Evaluation (APACHE) III score, and 
pharmacy data including bar code medication administration records.  Trained study personnel then 
manually extracted time of ED presentation, presence of shock and refractory shock, S. aureus appropriate 
antibiotic administration, and time from ED presentation to antibiotic presentation from the EMR using 
established chart review methodology [28].  We created a series of predetermined rules and a procedural 
manual for data extraction.  Two data extractors, blinded to the study outcome, were trained by the lead 
investigator and required to show competence extracting 20 charts prior to independent data abstraction. 
Time of ED presentation was defined as the date/time the first ED vital signs were entered into the EMR.  
Shock was considered to be present if participants had as a systolic blood pressure <90 mmHg, a mean 
arterial pressure (MAP) <65 mmHg, or if vasopressor agents were initiated.  Shock also had to have lasted 
for more than one hour and be refractory following 1000 ml of intravenous (IV) fluid.  If, however 
vasopressor agents were initiated and were infused for more than one hour, a participant was considered to 
have refractory shock even if his/her vital signs became normal. In cases for which a participant did not 
receive either IV fluid or vasopressors, a participant was considered to have refractory shock if he/she had 
one hour of sustained hypotension (Supplementary Table 1).  An a priori list of appropriate antibiotics was 
created for both MRSA and MSSA bacteremia (Supplementary Table 2).  The date/time of the first use of 
one of these antibiotics was recorded as the antibiotic administration time.  For cases in which multiple 
antibiotics were administered, the date/time of the first appropriate antibiotic recorded in the EMR was used 
in the analysis.  Time to antibiotic administration was calculated as the difference between time from ED 
presentation to appropriate antibiotic administration.  The outcome of interest, all-cause mortality within 30 
days of the first positive S. aureus blood culture, was electronically extracted from the EMR. 
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The Institutional Review Board and Research and Development Committee of the Providence VA 
Health System approved this study with a waiver of informed consent for patients.   
 
Statistical Analysis 
Participant clinical and demographic characteristics were summarized using descriptive statistics.  
Chained multiple imputation (n = 20) was used to impute missing values for body mass index (BMI, n=13), 
APACHE III score (n=4), and systemic inflammatory response syndrome (SIRS) criteria present at the time 
of blood culture (n=38). Fisher’s exact and Wilcoxon rank-sum tests were used to assess for differences 
between survivors and non-survivors for dichotomous and continuous characteristics, respectively.     
Logistic regression modeling was used to evaluate the relationship between time of appropriate 
antibiotic administration and 30-day mortality using the dataset containing the original and the imputed 
missing variables. Separate models were created for the entire study sample and stratified by participants 
whose S. aureus was classified as MRSA or MSSA, if shock preceded or followed antibiotic administration, 
and if shock developed within 12 hours or after 12 hours from ED presentation. Time to antibiotics 
administration was entered into the model as a linear continuous variable, based on the method of fractional 
polynomials.  We assessed 862 variables representing clinical characteristics including infections source, 
concomitant infections, APACHE score, medical history and current comorbidities as potential confounders 
of time to appropriate antibiotic therapy and mortality.  Additional variables considered for the model were 
those believed to have clinical relevance in the relationship of time to antibiotic administration and 
mortality. Confounders were considered further if they changed the time to antibiotics administration 
variable coefficient more than + 15%, regardless of statistical significance. Variables were considered to be 
effect-modifiers if they had a statistically significant interaction with the time to antibiotics administration. 
A stepwise forward selection process was used to create the final model.  Variables were retained in the 
model if they changed at least one other model coefficient by + 15%.  This produced a multivariate model 
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adjusted for: index year, BMI, APACHE III score, infective arthritis, SIRS criteria present at the time of 
blood culture, and MRSA/MSSA.  All analyses were performed using Stata/MP version 14.2.   
Results 
  
Participant Characteristics  
We identified 506 study participants with S. aureus bacteremia and septic shock who met our 
inclusion and exclusion criteria (Figure 1), 268 (53%) with MRSA and 238 (47%) with MSSA. The median 
age of study participants was 65 years old (interquartile range [IQR] 58-75), 98.2% were male, and the 
median APACHE III score was 66 (IQR 52-81).  We observed a significant amount of baseline organ 
dysfunction with a majority of participants having a concurrent diagnosis of a cardiovascular (91.3%), 
pulmonary (75.5%), rheumatologic (74.5%), hematologic (66.8%), central nervous system (64.2%), renal 
(60.9%), endocrine (60.1%), or psychiatric (59.3%) process (Table #1).  Details of specific diagnoses that 
comprised each organ system are outlined in the appendix (Supplementary Table 3). Thirty-day mortality 
was 78.1% for the entire cohort, and was similar for those participants with MRSA or MSSA (80.3% vs. 
76.1% p<0.28).  Univariate analysis showed that survivors were more likely than non-survivors to have a 
higher BMI, lower APACHE III score, a skin and soft tissue infection as the source of their bacteremia, and 
to have undergone surgery during hospitalization (Supplementary Table 4).   
Antibiotic Administration and Blood Cultures 
The median time to antibiotic administration from triage was 3 hours (IQR 1-5).  All participants 
received an a priori defined appropriate antibiotic. For cases of MRSA, 96.3% of the participants received 
vancomycin as the first antibiotic administered with anti-MRSA activity. For cases of MSSA, 40.3% 
received vancomycin, 30.5% piperacillin/tazobactam, 13.9% ceftriaxone or cefepime, and 10.3% 
levofloxacin, moxifloxacin, or ciprofloxacin as the first antibiotic with anti-MSSA activity.  Twenty-eight 
percent of participants received appropriate antibiotics upon arrival or within the first hour of care in the 
ED; 58.6% received antibiotics within the first 3 hours of care.  The distribution of antibiotic administration 
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is displayed in Figure 2.  Blood cultures were obtained in 95% of the participants within the first three days 
of hospitalization or in the two days preceding hospitalization.  
Primary outcome: 30-day Mortality  
Our multivariate analysis revealed that, as compared to those who received antibiotics within one 
hour following ED presentation, each additional hour that passed before antibiotics were administered 
produced an odds ratio of 1.11 (p=0.01) of 30-day mortality (Table 2 and Figure 3).  This odds increase 
equates to an average adjusted mortality increase of 1.3% [95% CI: 0.4% - 2.2%] for every hour that passes 
before antibiotics are administered (Supplementary Table 5).   The odds of mortality were not increased for 
time elapsed to antibiotic administration when participants were stratified by MRSA (OR 1.15; p=0.06) or 
MSSA (OR 1.08; p=0.12) status, and were similar for participants who developed shock either before (OR 
1.14; p=0.05) or after antibiotic administration (1.09; p=0.10; Table 2).  However, mortality was greater 
among the 298 participants who developed septic shock within 12 hours of ED presentation (OR 1.13; 
p=0.03).  
 
Discussion  
 
   We examined the relationship between timing of appropriate antibiotic administration and mortality 
among patients with septic shock due to S. aureus bacteremia in the Veterans Affairs Healthcare System.  
We found that each elapsed hour between time of ED presentation and antibiotic administration was 
associated with a 11% increase in the odds of 30-day morality.  This effect was most notable among patients 
who developed shock within 12 hours after ED presentation.   
Our findings enhance previous research on timing of antibiotic administration for patients with 
septic shock because we specifically focused on patients with S. aureus bacteremia.  Our study differs from 
most previous research as we have identified a population where 100% of the participants have confirmed 
bacteremia.  This dramatically reduces/eliminates the possibility that patients were included in our analyses 
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who were presumed to have septic shock but in fact in retrospect were never truly infected.  This potential 
misclassification may have diminished the findings of previous studies who reported an association between 
the timing of antibiotics and morality and were not able to document bacteremia among all participants.  
The high 30-day mortality among our study population (78%) underscores the importance of antibiotic 
administration timing when S. aureus is the culprit organism. The elevated mortality rate reflects the severe 
acuity of these patients who had a significant amount of concomitant baseline organ dysfunction requiring 
ICU admission for septic shock.  In comparison, in-hospital mortality among septic shock patients with non-
bacteremic or bacteremic shock (from a variety of bacterial species) is approximately 51% [29]. 
We recognize that antimicrobial culture results and sensitivity data are rarely available when a septic 
patient first presents to the ED.  Therefore, our study findings might only be practically applied for septic 
shock patients who are suspected to have S. aureus bacteremia. Nevertheless, S. aureus is the most common 
cause of septic shock [23].  When septic shock is believed to be secondary to skin/soft tissue, osteoarticular, 
endocarditis, and intravenous line or medical device infections, ED physicians will likely empirically 
administer antibiotics for S. aureus; whereas physicians may be less likely to consider a S. aureus infection 
in patients with pulmonary, abdominal or genitourinary infections.  In our study, only 39% of patients had a 
sepsis source that would likely have been identified during the ED history and physical examination as 
attributable to S. aureus (skin, endocarditis, and osteomyelitis/osteoarthritis), while the majority had a less 
obvious source of S. aureus septic shock (pulmonary or genitourinary). The importance of appropriate 
antibiotics is well recognized in sepsis and in cases of S. aureus bacteremia. Inappropriate antibiotic 
administration is associated with increased mortality [30]. Sepsis mortality among patients with MRSA 
bacteremia is greater than mortality for MSSA bacteremia [23-25]. Additionally, inadequate initial dosing of 
vancomycin for MRSA septic shock is associated with mortality [31]. Our observation of similar mortality 
rates for MRSA (80.3%) and MSSA (76.1%) is likely due to the severity of illness among our study 
population. Our stratified analysis suggests that time to antibiotic administration might be more critical for 
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patients with MRSA (OR=1.15) compared to patients with MSSA (OR=1.08), although these results did not 
reach statistical significance.  Rapid diagnostic techniques in the ED for S. aureus may have an important 
future role in identifying patients with S. aureus, and in differentiating MRSA from MSSA [32].  Until then, 
the results of this study suggest that physicians should empirically and rapidly administer broad spectrum 
antibiotics that include MRSA coverage for any case of suspected septic shock. 
Recent work using large healthcare system and state-wide databases has demonstrated an association 
between antibiotic delay and mortality among patients with sepsis [20, 21], with the most robust 
associations being observed for patients with septic shock. The Surviving Sepsis Campaign (SSC) and the 
Centers for Medicare and Medicaid Services (CMS) sepsis core measure both call for the prompt 
administration of antibiotics for all patients with sepsis and septic shock [2, 3].  A recent analysis of septic 
patients, the majority of whom had received antibiotics within the CMS three-hour window, suggests that 
even shorter delays in antibiotic administration may be harmful.  In their study, administration of antibiotics 
more than 125 minutes following sepsis identification (shock or SIRS criteria) was associated with 
increased mortality [33].  However, efforts to administer antibiotics quickly, especially in patients with 
lower illness severity, must be balanced with potential secondary harms.  These harms include renal injury, 
hepatitis, drug associated rashes, myelosuppression, the emergence of antibiotic resistance [34],  and 
expenditure of scarce ED resources [35].  While using robust methods, even well done analyses of large 
databases may suffer from unmeasured confounders and confounding by indication. This has led to calls to 
administer antibiotics as soon as septic shock is identified but adopt a more pragmatic approach towards 
septic patients where identification of organ dysfunction attributable to sepsis requires more time [36]. Our 
finding, that each hour delay in antibiotic administration is associated with a 1.3% increase in mortality 
among S. aureus septic shock patients is concordant with the septic shock subgroup described by Liu et al. 
(1.8%) [20], and suggests that physicians should quickly administer antibiotics in cases of septic shock.   
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Our study has limitations.  First, the observational study design cannot establish a causal relationship 
between the timing of antibiotic administration and mortality.  Second, the VA population is predominately 
male, which may limit the external validity of these findings to female patients with S. aureus bacteremia 
and septic shock.  While some data suggest that male patients develop bacteremia at a higher rate than 
female patients [37], data on gender differences in sepsis mortality are mixed [38-40].  Therefore, we 
suspect we would observe similar results if this analysis was performed in a predominately female cohort.  
Third, our observed 30-day mortality rate of 78.1% is high. As noted previously, we suspect the high 
mortality is due to the patients selected for the study (S. aureus bacteremia, ICU admissions directly from 
the ED, multiple baseline organ dysfunction, and septic shock). We observed a statistically significant 
decline in 30-day mortality from 85.7% in 2004 to 69.5% in 2015 (Supplementary Table 6) in the VA 
hospitals that follows a similar decreasing international trend during a similar time period [41].  Previous 
estimates of S. aureus bacteremia are less than our observed mortality rates, but in few instances are patients 
with S. aureus bacteremia and septic shock examined. A 2002 cross sectional observational study of 190 
ICUs across Europe found mortality rates of 37 and 42% for MSSA and MRSA sepsis, respectively, 
however less than half of these patient had septic shock [23].  Only small case control studies have 
examined patients with S. aureus bacteremia with concurrent septic shock and report mortality rates as high 
72%, which is consistent with the results of our study [31, 42].  Our use of ICD-9 diagnosis codes to identify 
patients with septic shock is subject to misclassification bias.  It is plausible that patients with septic shock 
who died were more likely to receive a formal diagnosis code of septic shock compared to septic shock 
patients who survived.  A strength of our study is that we combine ICD-9 diagnosis with additional clinical 
variables: positive blood cultures, independent confirmation of shock by chart review, and direct admission 
from the ER to ICU.  Combining ICD-9 diagnosis codes with clinical variables has been shown to increase 
the sensitivity and positive predicted value of the sepsis diagnosis code [43, 44], and the VA coding patterns 
for serious bacterial infection tend to be highly accurate [45]. Fourth, 41% of our study population 
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developed shock more than 12 hours after triage. In a stratified analysis among this group time to antibiotic 
administration was not associated with mortality.  This suggests that prompt administration of antibiotics 
may only be beneficial for septic patients who present in, or rapidly develop, shock.  Fifth, while stratified 
analyses suggested that a delay in antibiotic administration was associated with a higher odds ratio of 
mortality among patients with MRSA and for those patients who develop shock before antibiotic 
administration, these results did not reach statistical significance.  This is likely due to the relatively small 
sample size for these subgroups, which limited our ability to characterize mortality trends.  Further research 
that focuses on sepsis mortality and antibiotic administration in these populations is needed.  
Conclusion  
 In summary, among septic shock patients with S. aureus bacteremia admitted directly from the ED 
to the ICU, we found that each hour delay in appropriate antibiotic administration is associated with an 11% 
increase in the odds of 30-day mortality.  Physicians should consider acting quickly to administer antibiotics 
with S. aureus coverage to any patient suspected of having septic shock.  Future work should investigate the 
relationship between the timing of antibiotics and morality with other pathogens such as gram negative 
bacteria.  
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Figure Legends: 
Figure #1 Participant enrollment diagram.  
 
Figure #2 Kernel density plot showing time to antibiotic administration from emergency department triage. 
 
Figure #3 Odds ratios of 30-day mortality and the associated 95% confidence interval for time to first 
appropriate antibiotic administration.  Multivariate model adjusted for: BMI, APACHE III score, infective 
arthritis, SIRS criteria present at the time of blood culture, and MRSA/MSSA , and continuous time.
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